Such a method allows researchers to specifically investigate particular immune cell subgroups; indeed, differences in LRRK2 expression were reported in different immune cell types, with increases in non-classical, CD16+ monocytes specifically observed in PD patients relative to HCs (Cook et al., 2017). The gene discussed is LRRK2; the disease is Parkinson disease.